Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Board

Company Overview

Team

Values

Clinical Advisers

Corporate Directory

Corporate Governance

About Us

Presentations

In the News

Video Updates

Communication

Shareholder Services

US Shareholders

Investor Fact Sheet

Share Price

Announcements

Reports

Research Reports

Investor FAQs

Updates

Top 20 Shareholders

Investor Centre

Clinical Trial

Home

Webinars

Contact

Montserrat

Amplia Therapeutics Limited

upload.jpg

Amplia has received A$3.77 million under the Australian Government’s Research and Development Tax Incentive program for the financial year ended 31 March 2025.

The Australian Government's Research and Development Tax Incentive is a program to encourage businesses to undertake research and development (R&D) activities and provides eligible companies with a tax offset of 43.5%-48.5% (refundable) for eligible expenditure on R&D activities.

The refund relates to R&D expenditure for the development of the Company’s FAK inhibitors, including work undertaken as part of the ACCENT Phase 1b/2a clinical trial of narmafotinib (AMP945) in advanced pancreatic cancer.

These funds will be used to support the ongoing progression of the ACCENT and AMPLICITY trials, as well as further R&D activities.

Amplia Receives R&D Tax Rebate totalling $ 3.77 million